

23rd July, 2019

The Dy. General Manager (Listing Dept.)
BSE Limited.,
Corporate Relationship Dept.,
1st Floor, New Trading Ring,
P. J. Towers, Dalal Street, Fort,
Mumbai - 400 001
(BSE Scrip Code: 500420)

The Manager – Listing Dept.,
National Stock Exchange of India Ltd.,
Exchange Plaza, 5th Floor,
Plot No. C/1, G. Block,
Bandra - Kurla Complex, Bandra (E),
Mumbai – 400 051
(NSE Scrip Code: TORNTPHARM)

Dear Sir,

Sub.: Submission / Intimation under Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements), 2015, (“Listing Regulations”)

We would like to inform that the Board has at its meeting held today approved, inter-alia, the following:

- (a) Audited Standalone Financial Results along with audit report thereon and Unaudited Consolidated Financial Results along with the limited review report of the Company for the quarter ended on 30th June, 2019. The said financial results are enclosed herewith.

In terms of Regulation 47 of the Listing Regulations, the Company will publish an extract of Unaudited Consolidated Financial Results for the quarter ended on 30th June, 2019. Both Standalone and Consolidated Financial Results will be available at Company’s website www.torrentpharma.com.

A Press Release on Financial Results which is being submitted to the media is also enclosed herewith.

- (b) Approved the appointment of Shri Jinesh Shah as an Additional Director on the Board of the Company till the next Annual General Meeting and also Whole-time Director, designated as Director (Operations) for a period of 5 years with effect from 01-Aug-19 subject to approval of the shareholders. He is not related to any other Director of the Company. His brief profile is enclosed herewith as **Annexure – I**.

Further, we would like to inform that Shri Shah is not debarred from holding the office of director by virtue of any SEBI order or any other such authority.

TORRENT PHARMACEUTICALS LIMITED

CIN : L24230GJ1972PLG002126




The Board meeting commenced at 02:00 pm and concluded at 5:30 pm.

The above is for your information and record.

Thanking you,

Yours Sincerely,

For TORRENT PHARMACEUTICALS LIMITED



MAHESH AGRAWAL
VP (LEGAL) & COMPANY SECRETARY

Encl.: A/a

Annexure - I**PROFILE OF SHRI JINESH SHAH**

Shri Jinesh Shah, 42 years, is a Science graduate and MBA in International Business from USA. He started his professional career with the Company in 2001 as management trainee and since then he has not only played a key role in development of businesses in Russia and Europe markets but also acquired good insights in areas of manufacturing, supply chain management, product development & regulatory affairs. He had played a very important role in the successful acquisition of business from Elder Pharmaceuticals Ltd. as well as Unichem Laboratories Ltd. He is an excellent team player and has ensured effective coordination among various plants and R&D centre resulting in increased productivity for the organization.

He was elevated as Executive Director (Operations) w.e.f 1-Apr-14.

He has displayed affirmative management approach coupled with a positive leadership role. He is result oriented with strong focus on planning and implementation. An ardent believer in Torrent's values and philosophies, he imbibes them in all his thoughts and actions.

